MDxHealth (MDXH) Projected to Post Quarterly Earnings on Thursday

MDxHealth (NASDAQ:MDXH) is expected to post its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect MDxHealth to post earnings of ($0.13) per share and revenue of $26.0540 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

MDxHealth Stock Performance

Shares of MDXH stock opened at $3.68 on Thursday. The company’s 50 day moving average price is $3.50 and its two-hundred day moving average price is $3.72. MDxHealth has a 52 week low of $1.35 and a 52 week high of $5.33. The company has a market capitalization of $174.03 million, a P/E ratio of -5.75 and a beta of 1.64.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors and hedge funds have recently modified their holdings of the company. Intesa Sanpaolo Wealth Management acquired a new stake in MDxHealth in the 4th quarter valued at about $36,000. Lido Advisors LLC bought a new stake in MDxHealth in the third quarter valued at approximately $48,000. Squarepoint Ops LLC bought a new stake in MDxHealth in the fourth quarter valued at approximately $51,000. Jefferies Financial Group Inc. acquired a new stake in shares of MDxHealth in the third quarter valued at approximately $53,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of MDxHealth during the 4th quarter worth approximately $68,000.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MDXH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research report on Monday, December 29th. Lake Street Capital boosted their price objective on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. BTIG Research reaffirmed a “buy” rating and issued a $7.00 target price on shares of MDxHealth in a research report on Tuesday, December 23rd. Finally, TD Cowen lifted their price target on shares of MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, MDxHealth has a consensus rating of “Moderate Buy” and an average target price of $7.75.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.